The rural cancer population covered by TM experienced significantly higher annual all-cause mortality and lower hospice use in 2023, and spending per beneficiary, comorbidity burdens, and common cancer prevalence were comparable between beneficiaries accessing care in urban versus rural settings in TM.
T. Olsen, Robin K. Yabroff, E. Sharon· JCO Oncology Practice· 0 citations
A stakeholder-informed seven-criterion evaluation rubric spanning safety, reliability, and communication quality is developed and benchmarked 19 LLM judges across multiple implementation strategies, supporting LLM judges for scalable patient communication oversight while demonstrating the need for recalibration to pati...
BACKGROUND
Tumor mutational burden (TMB) has been established as a predictor of response to immune checkpoint inhibitors (ICI) ± chemotherapy in advanced non-small cell lung cancer (NSCLC). However, less is known about its role as a predictor of immune-related adverse events (irAEs) METHODS: This monocentric cohort stu...
F. Pecci, Xinan Wang, Valentina Santo et al.· Journal of Thoracic Oncology· 0 citations
This position article synthesizes key barriers in ICI therapy while highlighting emerging opportunities to refine patient selection, improve safety, and enhance therapeutic durability, position the field to move beyond the current plateau toward a more precise, effective, and patient-centered era of immuno-oncology.
Joud Hajjar, B. Stephen, A. Aaroe et al.· Journal of Immunotherapy and...· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.